The French beauty conglomerate deepens its presence in the aesthetics sector by taking a 10% additional stake in pure-play dermatology leader Galderma.WHO: Galderma was spun out of Nestlé in 2019 when a consortium led by private equity house EQT and including Singapore's GIC and the Abu Dhabi Investment Authority acquired the Nestlé Skin Health unit for $10 billion and rebranded it as Galderma. Since its inception in 1981, the business has been driven by a dedication to dermatology, delivering an innovative, science-based portfolio of sophisticated brands and services across aesthetics, consumer care, and prescription medicine. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. Galderma has more than doubled in size, growing from a €1.6 billion ($1.7 billion) to a €4.4 billion ($4.8 billion) company in 2024.For over 110 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. The company has a broad portfolio of 37 international brands and 87,400 committed employees, a balanced geographical footprint, and sales across all distribution networks. In 2022, L’Oréal Groupe generated sales amounting to 38.26 billion euros.